Quantcast

Industry news that matters to you.  Learn more

New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer

Reading time: 2 minutes

Veridex, LLC announced today that it has joined with Novartis Pharmaceuticals Corporation in an educational alliance to encourage and facilitate research involving circulating tumor cells, or CTCs, as a potential biomarker in metastatic prostate cancer.

As part of this initiative, Veridex will support a prospective, single arm, open-label study designed to investigate the effect of zoledronic acid* on CTCs in patients with metastatic castration-resistant prostate cancer (CRPC).

Dr. Ekkehardt Bismarck, M.D., of the EuromedClinic, Furth, Germany, one of the lead investigators, comments, “We hope to determine whether zoledronic acid may have an impact on CTC counts in the body. It is known that improvement of CTC counts has been associated with improved clinical outcomes.”

The study population will initially consist of a representative group of 60 CRPC patients with metastatic bone disease from five-to-10 study centers in Germany. The study will investigate the number of CTCs in study patients who receive zoledronic acid 4mg administered every four weeks for three months. The primary objective of the study is to determine the proportion of patients with decreased CTCs at 12 weeks after first infusion of zoledronic acid.

“Our alliance with Novartis further highlights the growing interest in CTCs as a potential biomarker in treating patients with metastatic prostate, breast and colorectal cancers,” said Robert McCormack, Ph.D. and Head of Technology Innovation at Veridex. “We look forward to further investigating the potential predictive benefit of CTCs in metastatic prostate cancer clinical studies as there are currently limited ways of assessing therapeutic benefit in this disease, especially when it has metastasized to the bone.”

“Our agreement with Novartis signifies our desire to collaborate with biopharmaceutical companies both internally and externally,” continued McCormack. “By leveraging our world-leading expertise in rare cell technology and developing current and future collaborations, we can drive to a more informed drug development model and help develop targeted treatments, making a significant difference for patients and their families.”

Source: PR Newswire